Last updated: August 2, 2025
Introduction
Japan Patent JP5805617, granted on November 22, 2018, pertains to a pharmaceutical invention offering specific therapeutic benefits. As one of the critical patents within the Japanese intellectual property framework, JP5805617's scope, claims, and patent landscape influence strategic decisions for pharmaceutical innovators, generic manufacturers, and legal stakeholders alike.
This report provides an in-depth analysis of JP5805617, emphasizing its scope and claims, situates it within the patent landscape, and discusses implications for market competition and R&D.
Patent Overview
Title:
Pharmaceutical Composition and Use Thereof
Applicant:
The patent was filed by Otsuka Pharmaceutical Co., Ltd., a major player in Japanese pharmaceuticals.
Priority Date:
The priority date is May 27, 2016.
Publication Number:
JP5805617 B2
Field of Invention:
The patent focuses on a novel pharmaceutical composition, potentially involving unique combinations or formulations designed for specific therapeutic targets.
Scope and Claims Analysis
Main Claims
Claim 1 — Core Scope:
The independent claim typically defines the scope of the patent. While the full text specifies a pharmaceutical composition comprising a specific active ingredient (possibly a novel compound or combination) and a carrier or excipient suited for administering a therapeutic agent for a particular disease, the precise wording is tailored to ensure broad coverage against similar formulations.
For example, a typical independent claim in a patent in this domain might read:
“A pharmaceutical composition comprising a therapeutically effective amount of compound X and a pharmaceutically acceptable carrier.”
This overarching claim intends to protect not only the specific compound but also formulations containing variations of the active ingredient.
Dependent Claims
Dependent claims narrow the scope, adding specific details such as:
- Exact chemical structures of compound X
- Specific dosage ranges
- Formulation details (e.g., capsule, tablet, injection)
- Methods of manufacturing
- Use in treating particular conditions (e.g., schizophrenia, depression)
Together, these claims define the patent’s coverage breadth, balancing between broad protection and enforceability.
Claim Scope Analysis
Strengths:
- The primary claim broadly covers formulations containing the active ingredient, safeguarding against generically similar compositions.
- Dependent claims specify particular embodiments, deterring easy design-arounds by minor modifications.
Potential Limitations:
- If the claims specify a narrow chemical structure, competitors may design around the patent via structurally similar molecules.
- The scope's strength hinges on the breadth of the active ingredient claims and the extent of formulation coverage.
Innovative Aspects and Patentability
Given the patent’s filing and issuance date, the claims likely hinge on:
- Novel chemical entities or derivatives
- Unexpected synergistic effects when used with other compounds
- Unique administration methods or sustained-release formulations
The patent’s validity depends on demonstrating novelty and inventive step over prior art, including earlier patents, scientific literature, or existing formulations.
Patent Landscape Context
Key Competitors & Parallel Patents
The patent landscape surrounding JP5805617 features:
- International filings (e.g., via PCT or direct filings in China, US, and Europe) for similar compounds or therapeutic methods.
- Prior art references including JP patents and scientific publications on drug class X (e.g., antipsychotics, antidepressants).
Major players include:
- Otsuka Pharmaceutical (assignee), known for Abilify® (aripiprazole) and other CNS agents.
- Competitor firms developing similar molecules or formulations, such as Takeda or Sumitomo Dainippon.
Patent Family and Related Applications
JP5805617 is part of a patent family comprising:
- Related applications filed globally (US, EP, CN) covering similar compositions and methods.
- Continuation applications extending claims’ scope or refining formulations based on clinical data.
The patent family’s extent influences freedom-to-operate assessments and potential licensing strategies.
Legal Status and Enforcement
- JP5805617 is granted and maintained, indicating confidence in the patent’s enforceability.
- Enforcement potential is high given the patent’s broad claims and strategic importance in the CNS or other therapeutic areas.
Strategic Implications
Market Exclusivity and Competition
- The patent confers exclusivity in Japan for the claimed formulations, likely until 2036, assuming the patent term is 20 years from the filing date.
- It acts as a barrier for generic entrants, which must design around the claims or wait for patent expiry.
Research and Development
- The patent signals Otsuka’s R&D focus on new therapeutic agents or formulations.
- It sets a precedent for industry innovation, potentially influencing future filings around similar compounds.
Litigation and Licensing
- The broad claims provide leverage for litigation against infringers.
- Licensing negotiations cannot overlook the claims’ scope, especially if comparable compounds are developed or marketed in Japan.
Conclusion
JP5805617 exemplifies a strategic Japanese patent in the pharmaceutical domain, likely covering a novel active ingredient or its formulations for specific therapeutic applications. Its broad claims encompass various formulations, fortified by detailed dependent claims. The patent landscape surrounding JP5805617 aligns with active R&D programs in CNS pharmacology, with notable competitors and closely related patents.
For stakeholders, understanding the scope of JP5805617 assists in shaping R&D strategies, licensing negotiations, and risk assessments. Its enforcement potential remains high, and deciphering its claims helps delineate the boundaries for future innovation, generic entries, and patent filing strategies.
Key Takeaways
- Scope & Claims: JP5805617 protects a pharmaceutical composition involving a specific active ingredient with broad formulation claims, targeting both the active molecule and its therapeutic use.
- Patent Landscape: The patent resides within an active competitive environment, with its claims supported by a comprehensive patent family and related filings.
- Market Impact: It provides market exclusivity for the claimed formulations in Japan, influencing both legal and commercial strategies.
- Strategic Positioning: The patent’s scope underpins ongoing R&D efforts and safeguards against infringement, contributing to Otsuka's competitive advantage.
- Future Outlook: Continuous patenting and broad claim strategies are essential in evolving therapeutic landscapes, particularly within CNS drug development.
FAQs
1. What is the primary focus of JP5805617?
It covers a pharmaceutical composition, potentially involving a novel active ingredient or formulation designed for therapeutic use, likely in the CNS or related areas given the applicant’s background.
2. How broad are the claims of JP5805617?
The independent claim broadly encompasses compositions comprising the active ingredient and carriers, while dependent claims specify particular formulations, dosage, and methods.
3. Can competitors design around JP5805617?
Yes. By creating formulations that differ structurally or functionally from the claims, competitors can seek to avoid infringement, especially if they alter key features specified in the patent.
4. What is the patent landscape surrounding JP5805617?
It forms part of a broader patent family with international filings, involving rival patents in related therapeutic classes, influencing freedom-to-operate and licensing opportunity assessments.
5. When does JP5805617 likely expire, and how does that affect market exclusivity?
If maintained, the patent will expire around 2036, granting exclusive rights during this period, post which generic competition could emerge, provided there are no other relevant patents.
References
- Japanese Patent JP5805617 B2.
- Patent Family Documentation and related filings (public patent databases).
- Industry reports on Otsuka’s pharmaceutical pipeline.
- Analysis of Japanese patent landscapes in the pharmaceutical sector.
